Daiichi Sankyo

News

SEC accuses former AstraZeneca exec of insider trading

The US Securities and Exchange Commission has sued a former AstraZeneca executive over alleged insider trading in connection with its 2019 deal to acquire rights to Daiichi Sankyo's breast

News

Takeda, Daiichi-backed wearable study planned in Japan

A study that will look at the feasibility of tracking people's lifestyle habits for an extended period using a wearable device has got underway in Japan, backed by drugmakers Takeda and Dai

News

Enhertu gets breakthrough tag in HER2-low breast cancer

AstraZeneca and Daiichi Sankyo have claimed a fifth breakthrough designation from the FDA for Enhertu, shortly after showing the drug extended survival in patients with HER2-low metastatic

News

FDA starts speedy review of Enhertu in lung cancer

AstraZeneca and Daiichi Sankyo should only have to wait for six months to hear from the FDA if it will approve their HER2 drug Enhertu for non-small cell lung cancer (NSCLC) and add to its

News

Seagen wins Enhertu patent dispute with Daiichi Sankyo

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages.

News

Big day for AZ, Daiichi as Enhertu aces HER2-low breast canc...

Already making inroads as a treatment for HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo's Enhertu has now shown efficacy in tumours that express lower levels of HER2 – potenti

SEC accuses former AstraZeneca exec of insider trading

Takeda, Daiichi-backed wearable study planned in Japan

Enhertu gets breakthrough tag in HER2-low breast cancer

FDA starts speedy review of Enhertu in lung cancer

Seagen wins Enhertu patent dispute with Daiichi Sankyo

Big day for AZ, Daiichi as Enhertu aces HER2-low breast canc...

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

Daiichi Sankyo

Editor's Picks